Yan Wang

33PUBLICATIONS
69CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|May 06, 2026
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non-Small Cell Lung Cancer.

|May 03, 2026
Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study.

|Jan 17, 2025
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors.

Linyan Tian, Chengming Liu, Sufei Zheng

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

|Nov 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

Dingzhi Huang, Gen Lin, Qian Chu

|Nov 01, 2023
Immunotherapy as a later-line option for <i>HER2</i>-altered advanced non-small-cell lung cancer: taxane might be a favorable partner.

Yaning Yang, Guangjian Yang, Weihua Li

Pageof 6

Frequent Collaborators

10 joint publications

Lu Yang

9 joint publications

Haiyan Xu

6 joint publications

Junling Li

4 joint publications

Puyuan Xing